Table 3.
Incidence rate ratios and estimated number of excess events per million for individual outcomes in the 1–42 days following vaccination or a SARS-CoV-2 positive test (before or after vaccination) compared to baseline period in children aged 5-11 years
| BNT162b2 vaccine | mRNA-1273 vaccine | ChAdOX1 vaccine | Positive SARS-CoV-2 test | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | IRR (95% CI) | Excess events (95% CI) | N | IRR (95% CI) | Excess events (95% CI) | N | IRR (95% CI) | Excess events (95% CI) | N | IRR (95% CI) | Excess events (95% CI) | |
| Multisystem inflammatory syndrome | ||||||||||||
| First dose/positive test (before vaccine) | < 5 | - | - | 0 | - | - | 0 | - | - | 226 | 11.52 (9.25, 14.36) | 137 (134, 140) |
| Second dose/positive test (after vaccine) | 0 | - | - | 0 | - | - | 0 | - | - | 0 | - | - |
| Third dose | 0 | - | - | 0 | - | - | 0 | - | - | |||
| Myocarditis | ||||||||||||
| First dose/positive test (before vaccine) | 0 | - | - | 0 | - | - | 0 | - | - | 6 | 14.00 (3.40, 57.67) | 4 (3, 4) |
| Second dose/positive test (after vaccine) | 0 | - | - | 0 | - | - | 0 | - | - | 0 | - | - |
| Third dose | 0 | - | - | 0 | - | - | 0 | - | - | |||
| Immune or idiopathic thrombocytopenia | ||||||||||||
| First dose/positive test (before vaccine) | 10 | * | - | 0 | - | - | 0 | - | - | 61 | * | - |
| Second dose/positive test (after vaccine) | <5 | * | - | 0 | - | - | 0 | - | - | 0 | * | - |
| Third dose | 0 | * | - | 0 | - | - | 0 | - | - | |||
| Epilepsy | ||||||||||||
| First dose/positive test (before vaccine) | 61 | 1.00 (0.76, 1.33) | 0 | 0 | - | - | 0 | - | - | 100 | 1.13 (0.91, 1.39) | 0 |
| Second dose/positive test (after vaccine) | 27 | 0.91 (0.60, 1.37) | 0 | 0 | - | - | 0 | - | - | < 5 | - | - |
| Third dose | 0 | - | - | 0 | - | - | 0 | - | - | |||
| Acute pancreatitis | ||||||||||||
| First dose/positive test (before vaccine) | < 5 | - | - | 0 | - | - | 0 | - | - | 9 | 2.69 (1.21, 5.97) | 4 (1, 5) |
| Second dose/positive test (after vaccine) | 0 | - | - | 0 | - | - | 0 | - | - | 0 | - | - |
| Third dose | 0 | - | - | 0 | - | - | 0 | - | - | |||
| Myositis | ||||||||||||
| First dose/positive test (before vaccine) | < 5 | - | - | 0 | - | - | 0 | - | - | 15 | 5.07 (2.62, 9.83) | 8 (6, 9) |
| Second dose/positive test (after vaccine) | 0 | - | - | 0 | - | - | 0 | - | - | 0 | - | - |
| Third dose | 0 | - | - | 0 | - | - | 0 | - | - | |||
| Acute disseminated encephalomyelitis | ||||||||||||
| First dose/positive test (before vaccine) | < 5 | - | - | 0 | - | - | 0 | - | - | 12 | 2.58 (1.32, 5.03) | 5 (2, 6) |
| Second dose/positive test (after vaccine) | 0 | - | - | 0 | - | - | 0 | - | - | 0 | - | - |
| Third dose | 0 | - | - | 0 | - | - | 0 | - | - | |||
| Demyelinating disease | ||||||||||||
| First dose/positive test (before vaccine) | < 5 | - | - | 0 | - | - | 0 | - | - | 6 | 1.80 (0.72, 4.52) | 0 |
| Second dose/positive test (after vaccine) | < 5 | - | - | 0 | - | - | 0 | - | - | 0 | - | - |
| Third dose | 0 | - | - | 0 | - | - | 0 | - | - | |||
| Appendicitis | ||||||||||||
| First dose/positive test (before vaccine) | 63 | 1.02 (0.78, 1.35) | 0 | 0 | - | - | 0 | - | - | 213 | 1.15 (0.99, 1.33) | 0 |
| Second dose/positive test (after vaccine) | 8 | 0.80 (0.39, 1.65) | 0 | 0 | - | - | 0 | - | - | <5 | - | - |
| Third dose | 0 | - | - | 0 | - | - | 0 | - | - | |||
| Guillain-Barre Syndrome | ||||||||||||
| First dose/positive test (before vaccine) | 0 | - | - | 0 | - | - | 0 | - | - | 0 | - | - |
| Second dose/positive test (after vaccine) | 0 | - | - | 0 | - | - | 0 | - | - | 0 | - | - |
| Third dose | 0 | - | - | 0 | - | - | 0 | - | - | |||
| Angioedema | ||||||||||||
| First dose/positive test (before vaccine) | < 5 | - | - | 0 | - | - | 0 | - | - | 12 | 1.01 (0.55, 1.87) | 0 |
| Second dose/positive test (after vaccine) | 0 | - | - | 0 | - | - | 0 | - | - | 0 | - | - |
| Third dose | 0 | - | - | 0 | - | - | 0 | - | - | |||
| Anaphylaxis | ||||||||||||
| First dose/positive test (before vaccine) | < 5 | - | - | 0 | - | - | 0 | - | - | 24 | 1.45 (0.91, 2.31) | 0 |
| Second dose/positive test (after vaccine) | 0 | - | - | 0 | - | - | 0 | - | - | 0 | - | - |
| Third dose | 0 | - | - | 0 | - | - | 0 | - | - | |||
N Number of events, IRR Incidence rate ratio, CI Confidence interval.
Cells with * are models that did not converge.